Josh Bilenker, Endpoints JPM 2020 (Jeff Rumans)
Josh Bilenker ends his brief role in an unusual experiment at Eli Lilly, bowing out as head of their Loxo cancer R&D unit
A little more than a year since Josh Bilenker started an unusual experiment running Eli Lilly’s cancer research group following the $8 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
